Compare · AMS vs ILMN
AMS vs ILMN
Side-by-side comparison of American Shared Hospital Services (AMS) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMS and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $24.58B, about 2524.1x AMS ($9.7M).
- Over the past year, AMS is down 40.0% and ILMN is up 85.5% - ILMN leads by 125.5 points.
- ILMN has been more active in the news (24 items in the past 4 weeks vs 2 for AMS).
- ILMN has more recent analyst coverage (25 ratings vs 0 for AMS).
- Company
- American Shared Hospital Services
- Illumina Inc.
- Price
- $1.44-5.26%
- $162.43+1.51%
- Market cap
- $9.7M
- $24.58B
- 1M return
- -23.40%
- +14.03%
- 1Y return
- -40.00%
- +85.49%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- AMEX
- NASDAQ
- IPO
- 1988
- 2000
- News (4w)
- 2
- 24
- Recent ratings
- 0
- 25
American Shared Hospital Services
American Shared Hospital Services leases radiosurgery and radiation therapy equipment to health care providers. The company offers radiosurgery equipment for the Gamma Knife stereotactic radiosurgery, a non-invasive procedure to treat malignant and benign brain tumors, and arteriovenous malformations, as well as for trigeminal neuralgia. It also provides financing services for Leksell Gamma Knife units. In addition, the company offers proton beam radiation therapy services in Orlando, Florida and Long Beach, California, as well as offers planning, installation, reimbursement, and marketing support services to its customers. As of March 1, 2021, it had thirteen operating Gamma Knife units located in the United States, as well as two in South America in Lima, Peru and Guayaquil, Ecuador. The company also operates one PBRT system. American Shared Hospital Services was founded in 1980 and is headquartered in San Francisco, California.
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest AMS
- American Shared Hospital Services filed SEC Form 8-K: Events That Accelerate or Increase a Direct Financial Obligation
- American Shared Hospital Services Announces Annual Shareholder Meeting to be Held on June 24, 2026
- SEC Form 10-Q filed by American Shared Hospital Services
- American Shared Hospital Services filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- American Shared Hospital Services Reports First Quarter 2026 Financial Results
- American Shared Hospital Services Announces First Quarter 2026 Financial Results Conference Call
- SEC Form DEFA14A filed by American Shared Hospital Services
- SEC Form DEFA14A filed by American Shared Hospital Services
- SEC Form DEF 14A filed by American Shared Hospital Services
- American Shared Hospital Services filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
Latest ILMN
- Illumina upgraded by Analyst with a new price target
- SVP, Chief People Officer Leckman Patricia sold $127,305 worth of shares (783 units at $162.59), decreasing direct ownership by 4% to 21,259 units (SEC Form 4)
- Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution
- SVP, Chief People Officer Leckman Patricia sold $127,068 worth of shares (784 units at $162.08), decreasing direct ownership by 3% to 22,042 units (SEC Form 4)
- Director Meister Keith A. sold $107,042,631 worth of shares (669,596 units at $159.86) (SEC Form 4)
- Chief Legal Officer Davies Scott M sold $98,400 worth of shares (615 units at $160.00), decreasing direct ownership by 3% to 21,568 units (SEC Form 4)
- VP, Chief Accounting Officer Ericksen Scott D sold $305,150 worth of shares (2,000 units at $152.57), decreasing direct ownership by 12% to 14,446 units (SEC Form 4)
- Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights
- Amendment: SEC Form 4 filed by Director Meister Keith A.
- Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research